AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
2.680
-0.060 (-2.19%)
At close: Oct 1, 2025, 4:00 PM EDT
2.680
0.00 (0.00%)
After-hours: Oct 1, 2025, 6:15 PM EDT
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $25.00K in the quarter ending June 30, 2025, a decrease of -50.00%. This brings the company's revenue in the last twelve months to $121.00K, down -39.80% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.
Revenue (ttm)
$121.00K
Revenue Growth
-39.80%
P/S Ratio
62.64
Revenue / Employee
$5,261
Employees
23
Market Cap
7.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AIM News
- 6 days ago - AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors - GlobeNewsWire
- 27 days ago - AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 2 months ago - AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval - GlobeNewsWire
- 2 months ago - Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga